How Cerebral Plasticity Shapes Symptom Progression in Parkinson's Disease: A Longitudinal Neuroimaging Study

Completed

Conditions: Parkinson's disease
10028037

Registration Number: NL-OMON46228

Lead Sponsor: Radboud Universiteit Nijmegen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 120

Inclusion Criteria

General:
1) *40 years old.
2) Able to read and understand Dutch.
3) Subject is willing, competent, and able to comply with all aspects of the protocol, including
follow-up schedule.
Parkinson's Disease-specific:
1) Participation in motor and reward tasks Personalized Parkinson Project (NL59694.091.16)
2) Subject has Parkinson*s disease of *5 years* duration, defined as time since diagnosis made by a neurologist.

Exclusion Criteria

1) Subject has co-morbidities that would hamper interpretation of parkinsonian disability or task performance, such as coincident musculoskeletal abnormalities, in the opinion of the investigator.
2) Contraindicated for MRI, e.g., claustrophobia, presence of an active implant, pacemaker, insulin pump, neurostimulator, ossicle prosthesis, pregnancy, and/or other medical device or other non-removable metal part incompatible with MRI.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>For this study, we will assess 50 patients with PD once (OFF their dopaminergic<br /><br>medication) and 50 healthy volunteers twice (baseline and two-year follow up).<br /><br>We will use a subset of the protocols used in the PPP, in which 650 PD patients<br /><br>are assessed ON their dopaminergic medication. This protocol includes two<br /><br>functional MRI tasks (motor task in first half (n=325) of patients, reward task<br /><br>in second half (n=325) of patients) that quantify both (dysfunctional)<br /><br>processing in the basal ganglia and (compensatory) processing in the cortex<br /><br>(i.e. parietal cortex for the motor task, orbito-frontal cortex for the reward<br /><br>task). We will quantify clinical disease progression with clinical measures<br /><br>such as the MDS-UPDRS. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters include participant characteristics (e.g. Age,<br /><br>Gender, Comorbidity, Medication use), clinical measures (e.g. severity of<br /><br>motor, cognitive and neuropsychiatric symptoms), and additional MRI-measures<br /><br>(Resting state functional connectivity, Diffusion tensor imaging, Quantitative<br /><br>susceptibility imaging and fluid-attenuated inversion recovery) to be used for<br /><br>thorough interpretation of primary outcomes. </p><br>